CG Oncology, Inc.
CGONNasdaq
$71.85
↑ +3.4%Jul 17 close · end-of-day
Price
1Y↑ +175.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.1B
Enterprise Value
$5.0B
P/E
—
P/S
1197.5
P/B
5.6
EV/EBITDA
—
PEG
—
FCF Yield
-2.6%
Dividend Yield
—
Revenue (TTM)
$5.1M
Net Income (TTM)
-$186.8M
Free Cash Flow (TTM)
-$160.4M
Gross Margin
—
Operating Margin
-4239.0%
Net Margin
-3682.7%
ROE
-17.1%
ROIC
-916.1%
Debt / Equity
0.0
Net Cash
$1.1B
Return 1Y
+152.5%
Company profile
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We were originally founded as a California corporation on September 24, 2010 under the name Cold Genesys, Inc. On November 30, 2017, we reincorporated as a Delaware corporation, and on March 31, 2020, we changed our name to CG Oncology, Inc. Our principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA.
- CEO
- Arthur Kuan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- cgoncology.com
Earnings
CGON Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.1M↑ +1982.7%
Diluted EPS-$0.71↑ +57.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $204,000.00 | $1.1M | $4.0M |
| Gross profit | — | — | — |
| Operating income | -$55.4M | -$114.7M | -$190.8M |
| Net income | -$48.6M | -$88.0M | -$161.0M |
| Diluted EPS | -$15.65 | -$1.41 | -$2.08 |
| Operating cash flow | -$45.7M | -$78.7M | -$132.3M |
| Free cash flow | — | -$78.9M | -$132.5M |
| Gross margin | — | — | — |
| Operating margin | -27180.9% | -10067.3% | -4722.1% |
| Net margin | -23827.0% | -7729.6% | -3985.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $111,000.00 | $43,000.00 | $456,000.00 | $52,000.00 | $0.00 | $1.7M | $2.3M | $1.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$25.9M | -$28.3M | -$38.0M | -$42.2M | -$48.7M | -$51.1M | -$48.7M | -$66.4M |
| Net income | -$18.9M | -$20.4M | -$31.8M | -$34.5M | -$41.4M | -$43.8M | -$41.3M | -$60.2M |
| Diluted EPS | -$0.28 | -$0.30 | -$0.47 | -$0.45 | -$0.54 | -$0.57 | -$0.52 | -$0.71 |
| Operating cash flow | -$16.1M | -$15.9M | -$20.7M | -$29.3M | -$28.0M | -$38.9M | -$36.2M | -$56.9M |
| Free cash flow | -$16.1M | -$15.9M | -$20.9M | -$29.3M | -$28.0M | -$39.0M | -$36.2M | -$57.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -23291.0% | -65802.3% | -8344.1% | -81161.5% | — | -3069.0% | -2097.3% | -6130.1% |
| Net margin | -17028.8% | -47453.5% | -6973.5% | -66253.8% | — | -2629.5% | -1779.2% | -5558.8% |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | POST LEONARD E | Sale | 1,000 | $71.17 | $71,170.00 | filing |
| 2026-07-15 | POST LEONARD E | Option exercise | 1,000 | $0.60 | $600.00 | filing |
| 2026-07-10 | Mulay James | Sale | 24,165 | $75.16 | $1.8M | filing |
| 2026-07-10 | Mulay James | Option exercise | 24,165 | $26.63 | $643,513.95 | filing |
| 2026-06-25 | Liu Brian Guan-Chyun | Buy | 371,085 | $66.87 | $24.8M | filing |
| 2026-06-24 | POST LEONARD E | Sale | 5,000 | $70.00 | $350,000.00 | filing |
| 2026-06-24 | POST LEONARD E | Option exercise | 5,000 | $0.60 | $3,000.00 | filing |
| 2026-06-22 | POST LEONARD E | Sale | 5,000 | $65.00 | $325,000.00 | filing |
| 2026-06-22 | POST LEONARD E | Option exercise | 5,000 | $0.60 | $3,000.00 | filing |
| 2026-06-15 | Mulay James | Sale | 1,310 | $60.12 | $78,757.20 | filing |
| 2026-06-15 | Mulay James | Sale | 654 | $60.12 | $39,318.48 | filing |
| 2026-06-15 | Mulay James | Option exercise | 1,310 | $12.59 | $16,492.90 | filing |
| 2026-06-15 | Mulay James | Option exercise | 654 | $3.72 | $2,432.88 | filing |
| 2026-06-04 | POST LEONARD E | Sale | 1,000 | $54.50 | $54,500.00 | filing |
| 2026-06-04 | POST LEONARD E | Option exercise | 1,000 | $0.60 | $600.00 | filing |
| 2026-04-17 | Mulay James | Sale | 15,600 | $73.01 | $1.1M | filing |
| 2026-04-17 | Mulay James | Option exercise | 15,600 | $36.63 | $571,428.00 | filing |
| 2026-03-16 | Mulay James | Sale | 1,310 | $63.50 | $83,185.00 | filing |
| 2026-03-16 | Mulay James | Sale | 654 | $63.50 | $41,529.00 | filing |
| 2026-03-16 | Mulay James | Option exercise | 1,310 | $12.59 | $16,492.90 | filing |
| 2026-03-16 | Mulay James | Option exercise | 654 | $3.72 | $2,432.88 | filing |
| 2026-03-12 | Kuan Arthur· Chief Executive Officer | Option exercise | 64,612 | $1.72 | $111,132.64 | filing |
| 2026-03-12 | Kuan Arthur· Chief Executive Officer | Tax withholding | 1,847 | $60.15 | $111,097.05 | filing |
| 2026-03-04 | Kuan Arthur· Chief Executive Officer | Option exercise | 102,871 | $1.72 | $176,938.12 | filing |
| 2026-03-04 | Kuan Arthur· Chief Executive Officer | Tax withholding | 2,871 | $61.61 | $176,882.31 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.